Physician profile
Roy Elrod
NPI 1306883541
$2,324.09
in general payments reported to CMS, 2019-2025
15 companies · $261 in 2025
The $261 reported for 2025 was more than what 85% of Emergency Medical Services providers received nationally (typical 2025 total: $70.35).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $472 · 2020: $16.03 · 2021: $11.90 · 2023: $971 · 2024: $592 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,824.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $378.37 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Teva Pharmaceuticals USA, INC. | $276.41 | 2019 | |
| Abbvie INC. | $239.90 | 2024 | |
| Glaxosmithkline, LLC. | $216.90 | 2023-2025 | Arexvy |
| Amgen INC. | $207.12 | 2019-2024 | Repatha |
| Lilly USA, LLC | $140.93 | 2019-2024 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $136.06 | 2023 | |
| Boston Scientific Corporation | $130.85 | 2023 | Watchman Access System |
| Modernatx, INC. | $120.66 | 2023 | Moderna Covid-19 Vaccine |
| Abbott Laboratories | $117.01 | 2023 | Freestyle Libre 2 |
| Sanofi Pasteur INC. | $111.16 | 2023 | |
| Alnylam Pharmaceuticals INC. | $110.88 | 2023 | Amvuttra |
| Novartis Pharmaceuticals Corporation | $102.06 | 2019 | |
| Exact Sciences Corporation | $23.88 | 2025 | The Cologuard Plus Collection Kit |
| Nestle Healthcare Nutrition INC. | $11.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Elrod listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.